The requirements for viral and host protein synthesis in the generation of target antigens for cytotoxic T lymphocytes (CTL) was evaluated by using vesicular stomatitis virus (VSV) inactivated by UV irradiation (UV-VSV). EL4 target cells incubated with UV-VSV were recognized and lysed by anti-VSV CTL, indicating that de novo synthesis of viral proteins was not required for the generation of antigens recognized by antiviral CTL. Anti-VSV CTL from H-2b mice primarily recognize determinants derived from the VSV N protein bound to the class I major histocompatibility complex (MHC) antigen H-2Kb. Comparison of a cloned CTL line representing this specificity and a heterogeneous population of anti-VSV CTL showed that determinants other than that recognized by the cloned CTL were generated more efficiently from UV-VSV. By using vaccinia virus recombinants that express deletion fragments of the N protein, it was shown that these additional determinants were probably derived from VSV proteins other than the N protein. The protein synthesis inhibitor emetine was used to determine whether newly synthesized host proteins were required for antigen generation. The addition of emetine to target cells prior to or at the time of the addition of UV-VSV inhibited lysis by anti-VSV CTL. This inhibition could be due to depletion of newly synthesized MHC molecules from intracellular membranes. This hypothesis was supported by using brefeldin A to delay membrane protein transport in target cells during the time of incubation with emetine and UV-VSV, which resulted in partial reversal of the effect of emetine. These results suggest that newly synthesized class I MHC molecules are required for the generation of antigens recognized by anti-VSV CTL.
The requirements for viral and host protein synthesis in the generation of target antigens for cytotoxic T lymphocytes (CTL) was evaluated by using vesicular stomatitis virus (VSV) inactivated by UV irradiation (UV-VSV). EL4 target cells incubated with UV-VSV were recognized and lysed by anti-VSV CTL, indicating that de novo synthesis of viral proteins was not required for the generation of antigens recognized by antiviral CTL. Anti-VSV CTL from H-2b mice primarily recognize determinants derived from the VSV N protein bound to the class I major histocompatibility complex (MHC) antigen H-2Kb. Comparison of a cloned CTL line representing this specificity and a heterogeneous population of anti-VSV CTL showed that determinants other than that recognized by the cloned CTL were generated more efficiently from UV-VSV. By using vaccinia virus recombinants that express deletion fragments of the N protein, it was shown that these additional determinants were probably derived from VSV proteins other than the N protein. The protein synthesis inhibitor emetine was used to determine whether newly synthesized host proteins were required for antigen generation. The addition of emetine to target cells prior to or at the time of the addition of UV-VSV inhibited lysis by anti-VSV CTL. This inhibition could be due to depletion of newly synthesized MHC molecules from intracellular membranes. This hypothesis was supported by using brefeldin A to delay membrane protein transport in target cells during the time of incubation with emetine and UV-VSV, which resulted in partial reversal of the effect of emetine. These results suggest that newly synthesized class I MHC molecules are required for the generation of antigens recognized by anti-VSV CTL.
Cytotoxic T lymphocytes (CTL) recognize viral antigens complexed with host proteins of the major histocompatibility complex (MHC), usually class I MHC molecules, at the surface of infected cells. Peptide fragments derived from the proteolysis of viral proteins bind to a cleft in the class I MHC molecule formed by the highly polymorphic otl and (x2 domains (reviewed by Townsend and Bodmer [20] ). The antigens recognized by class I MHC-restricted CTL are similar to antigens presented to helper T cells by class II MHC molecules in specialized antigen-presenting cells. As a general rule, antigens that bind to class II MHC molecules are derived from the uptake of exogenous proteins by endocytosis, while antigens associated with class I MHC molecules are primarily derived from intracellular sites such as the cytosol (reviewed by Yewdell and Bennink [27] ). It is likely that many viral antigens recognized by class I MHCrestricted CTL are generated by de novo synthesis during virus infection, since in some cases CTL recognition of target cells can be prevented by the inhibition of viral protein synthesis (14) . However, there are also examples of CTL recognition of antigens generated without protein biosynthesis. For instance, enveloped viruses inactivated by UV irradiation or heat treatment can sensitize target cells for CTL recognition, provided that the inactivated virions are capable of penetration into the cytosol by the fusion of the virus envelope with cellular membranes (9, 28) . Cells have also been shown to process antigens from exogenously added proteins introduced into the cytosol by the osmotic lysis of pinosomes (13) .
We have previously shown that vesicular stomatitis virus (VSV) inactivated by UV irradiation (UV-VSV) can be * Corresponding author. efficiently used in the secondary elicitation of CTL in vitro (3) . As in the case of CTL elicited by infectious virus (16), the anti-VSV CTL elicited by UV-inactivated virus in H-2b mice primarily recognize determinants derived from the major viral nucleoprotein (N protein) and are primarily restricted by H-2Kb. The results presented here extend these observations to show that UV-VSV can be used to sensitize target cells for lysis by anti-VSV CTL. This is an important distinction, since CTL elicitation using heterogeneous spleen cell cultures could conceivably involve a function restricted to specialized antigen-presenting cells that process UV-inactivated virus, as shown recently for the presentation of ovalbumin to class I MHC-restricted T cells (17) .
The processing pathway by which antigen fragments derived from cytoplasmic proteins associate with class I MHC molecules is unknown. Recent evidence indicates that the inhibition of class I MHC transport from the endoplasmic reticulum (ER) prevents the CTL recognition of target cells, suggesting that newly synthesized MHC molecules are required for antigen presentation (8, 15, 26 Anti-VSV CTL. The secondary elicitation of anti-VSV CTL from C57BL/6 mice in vitro by using UV-VSV was performed as described previously (3) . Anti-VSV CTL clone 33, derived from a C57BL/6 mouse, was obtained from James Sheil (West Virginia University School of Medicine) and was maintained by restimulation with irradiated spleen cells from H-2Kbm8 mice as described previously (18) . The conditions for the infection of target cells, labeling with 51Cr, and incubation with effector cells have been described previously (3) . Briefly, EL4 cells were incubated with either infectious VSV (10 to 30 PFU per cell) or UV-VSV for 30 min to 1 h. MC57G cells were infected with vaccinia virus recombinants for 7 h. Cells were labeled with 51Cr for 1.5 h and then incubated with effectors in a 4-h 51Cr release assay.
Generation of deletion fragments of the N gene. The plasmid pUC18/N was constructed by subcloning a 1.4-kbp XhoI fragment from pJS223 (19) 423 by ligation with an annealed mixture of the oligonucleotides 5'AGCTTGTCGACCACCATGTC and 5'C GGACATGGTGGTCGACA. The ligation mixtures were digested with HindIlI to remove multiple copies of the oligonucleotides, and the N gene fragments were cloned into the HindIII site of pUC18. The correct insertion of the oligonucleotides was confirmed by dideoxy sequencing on supercoiled templates, as described previously (6) .
Vaccinia virus recombinants. The vaccinia virus expression vector pSC11 (5) was modified to accept HindIII inserts by changing the original HindIII site to a BglII site and the SmaI site to a Hindlll site by restriction enzyme cleavage followed by ligation with the appropriate linkers (New England Biolabs, Beverly, Mass.). The N gene fragments were subcloned into the new HindIII site in the coding orientation under the control of the vaccinia virus 7.5K promoter. Transfection of CV1 cells infected with wild-type vaccinia virus and isolation of recombinants containing plasmid sequences was performed as described previously (5) . The vaccinia virus recombinant that expresses the full-length N protein has been previously described (12, 29) . RESULTS UV-VSV was tested for its ability to sensitize target cells for lysis by anti-VSV CTL. Anti-VSV CTL effectors were elicited by the secondary in vitro stimulation of primed spleen cells from C57BL/6 (H-2b) mice with UV-VSV. EL4 target cells were incubated with various concentrations of UV-VSV for 30 min. Cells were then labeled with 51Cr and incubated with anti-VSV CTL at various effector-to-target ratios. The data in Fig. 1 anti-VSV CTL population. In contrast, cells sensitized with UV-VSV are killed as efficiently by the heterogeneous population as by the cloned CTL. Thus, targets sensitized with UV-VSV expressed the epitope recognized by clone 33 CTL; however, a significant percentage of the heterogeneous anti-VSV CTL population must have recognized additional determinants in targets generated with UV-VSV to account for its relative efficiency of killing compared with that of the clone 33 CTL. The epitope recognized by clone 33 CTL consists of amino acids 52 to 59 of the N protein (23) . This was shown by using a set of overlapping chemically synthesized peptides corresponding to the amino terminal one-third of the N protein (amino acids 1 to 161) and by analysis of an endogenous peptide bound to H-2Kb isolated from VSV-infected cells. The additional determinants recognized by the heterogeneous anti-VSV CTL population could be derived either from sequences of the N protein other than the atnino terminal one-third or else from VSV proteins other than the N protein. Anti-VSV CTL were tested for their ability to lyse target cells infected with vaccinia virus recombinants expressing deletion fragments of the N protein to determine whether other determinants derived from the N protein were recognized, as shown in Fig. 3 Target cells sensitized with UV-VSV were used to determine whether viral antigens associate only with newly synthesized class I MHC molecules by incubating the cells with the protein synthesis inhibitor emetine. EL4 cells were incubated with emetine for various times before and after the addition of UV-VSV. Cells were then labeled with 51Cr and incubated with anti-VSV effector cells. Since emetine is an irreversible inhibitor of protein synthesis, it was not necessary to maintain the cells in medium with emetine throughout the incubation with effectors. In contrast, reversible inhibitors of protein synthesis, such as cycloheximide, were found to be toxic to effector cell function when included throughout the experiment (data not shown), as reported previously (4) . The data in Fig. 4 indicate that when emetine was added 1 h after the addition of virus, there was little or no inhibition of CTL recognition and lysis. When emetine was added at the time of the addition or 30 min after the addition of virus, there was partial inhibition, and when emetine was added 1 or 2 h before the addition of virus, there was significant inhibition of CTL recognition. These results suggest that newly synthesized MHC molecules are required for antigen recognition by anti-VSV CTL. Alternatively, the emetine could be inhibiting other processes in target cells required either for antigen presentation or for lysis by CTL. To rule out the latter possibility, EL4 cells were incubated with emetine either before or after the addition of the chemically synthesized N peptide corresponding to amino acids 52 to 59. Exogenous peptides appear to be able to bind to surface MHC molecules, bypassing the intracellular processing pathway (8, 13, 15, 26) . Figure 5 demonstrates that targets incubated with the peptide either before or after the H-2Kb was obtained by using brefeldin A (BFA) to delay membrane protein transport. BFA reversibly inhibits the transport of membrane proteins, such as MHC molecules (8, 15) , out of the ER. EL4 cells were incubated with BFA for 1 h before the addition of emetine and then of UV-VSV. The cells were incubated in the presence of BFA for an additional DISCUSSION Antigens associated with class I MHC molecules are generated by an as yet unidentified proteolytic degradation process. There is evidence to support the idea that the processing pathways for these antigens use a cytosolic route (reviewed by Yewdell and Bennink [27] (3) or are transfected with the G gene (16) . Therefore, the additional epitopes probably reside on the other internal viral proteins, the L, NS, or M protein.
Previous experiments have suggested that newly synthesized MHC molecules are required for antigen presentation.
For example, inhibition of the transport of class I MHC molecules to the cell surface prevents the recognition of viral antigens by CTL (8, 15, 26) . In addition, some class I MHC molecules require antigenic peptides for proper folding and association with 12 microglobulin, which are necessary for transport out of the ER (21) . Since class I MHC molecules on the cell surface have been shown to undergo recycling to intracellular membranes (22) , these results do not rule out the possibility that previously synthesized MHC molecules also present antigens after being recycled to intracellular sites of antigen-MHC association. To test this possibility, we used the protein synthesis inhibitor emetine to prevent the synthesis of MHC molecules in cells incubated with UV-VSV. The logic is that the addition of emetine for a sufficient time prior to the addition of virus should result in the depletion of MHC molecules from intracellular membranes due to the transport of the MHC molecules to the cell surface. The addition of emetine 1 to 2 h prior to the addition of antigen inhibits CTL recognition with cells treated with UV-VSV but not with cells treated with exogenously added antigenic peptide, which bypasses the intracellular pathway of antigen generation. These data support the idea that newly synthesized MHC molecules are required for antigen presentation, although they do not rule out 
